EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Prolonged haematologic toxicity in CAR‐T ‐cell therapy: A review

Qi Liu iD, Tonglin Hu, Hangchao Li, Yingying Shen, Dijiong Wu iD, Baodong Ye

Journal of Cellular and Molecular Medicine · 2023-12 · 27 (23) · 3662-3671

DOI: 10.1111/jcmm.17930 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 13.09.2023. Verfasst von Qi Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Ha…. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Hematologic Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health technology Plan of Zhejiang Province, National Natural Science Foundation of China, Project of Zhejiang Famous Traditional Chinese Medicine Expert Inheritance Studio Construction under Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor‐T‐cell (CAR‐T‐cell) therapy is a novel immunotherapy with encouraging results for treatment of relapsed/refractory haematologic malignancies. With increasing use, our understanding of immune‐mediated side effects such as cytokine release syndrome and neurotoxicity has improved; nevertheless, prolonged haematologic toxicity (PHT), with a high incidence rate, remains underrecognized. Owing to heterogeneity in populations, the CAR‐T cells used and diseases treated as well as differences in the definition of PHT, its rate, risk factors and management vary across studies. In this review, we provide a narrative of PHT occurring in patients following CAR‐T‐cell therapy; evidence of PHT treatment strategies is also presented, with the aim of contributing to systematic understanding of PHT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenHematologic NeoplasmsHumansNeoplasm Recurrence, LocalImmunotherapy, AdoptiveImmunotherapyCell- and Tissue-Based Therapy

Stichwörter der Autor:innen

CAR-T-cell therapymanagementmechanismprolonged haematologic toxicity

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China.
  • The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.

ORCID-Profile: Qi Liu, Dijiong Wu

Förderung

  • Health technology Plan of Zhejiang Province
  • National Natural Science Foundation of China
  • Project of Zhejiang Famous Traditional Chinese Medicine Expert Inheritance Studio Construction under Grant
  • Zhejiang Scientific Research Fund of Traditional Chinese Medicine

Zitieren

APA

Liu, Q., Hu, T., Li, H., Shen, Y., Wu, D., & Ye, B. (2023). Prolonged haematologic toxicity in CAR‐T ‐cell therapy: A review. Journal of Cellular and Molecular Medicine, 27(23), 3662-3671. https://doi.org/10.1111/jcmm.17930

Vancouver

Liu Q, Hu T, Li H, Shen Y, Wu D, Ye B. Prolonged haematologic toxicity in CAR‐T ‐cell therapy: A review. Journal of Cellular and Molecular Medicine. 2023;27(23):3662-3671. doi:10.1111/jcmm.17930

BibTeX
@article{Liu2023,
  author = {Liu, Qi and Hu, Tonglin and Li, Hangchao and Shen, Yingying and Wu, Dijiong and Ye, Baodong},
  title = {Prolonged haematologic toxicity in CAR‐T ‐cell therapy: A review},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2023},
  volume = {27},
  number = {23},
  pages = {3662--3671},
  doi = {10.1111/jcmm.17930}
}
Kostenlos starten →